CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

India's Gland Pharma beats quarterly estimates on strong Europe, US sales

By Reuters News

Nov 6 (Reuters) - India's Gland Pharma GLAD.NS reported a bigger-than-expected 58.3% jump in second-quarter profit on Friday, boosted by strong sales in its key European and US markets.

The Hyderabad-based company's consolidated net profit of 2.91 billion rupees ($30.9 million) was up from 1.84 billion rupees a year ago, beating analysts' average estimate of 2.75 billion rupees, according to data compiled by LSEG.


Here are some more details:

  • Its US sales, which make up more than half of the total, rose 42% in the quarter ended September 30, while the European business climbed 30%

  • Gland Pharma's results have consistently improved since a recovery in production at its Cenexi units in France and Belgium in late 2025

  • Disruption at these units had hurt the drugmaker's results throughout most of last year

  • Overall quarterly revenue rose 23.3% to 18.34 billion rupees, also beating estimates of 17.59 billion rupees

  • Gland Pharma and several of its Indian generic drugmaker peers that derive a large share of their revenue from the US have been grappling with limited pricing power amid stiff competition in that market

  • Larger rivals Cipla CIPL.NS and Dr Reddy's REDY.NS also reported subdued US sales during the second quarter


($1 = 94.1550 Indian rupees)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.